Unlocking the Power of the Microbiome
Paris/France—January 8, 2021: Biomillenia and Amyris, Inc., a leading synthetic biotechnology company in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty, and Flavors & Fragrances markets, announced today the signing of a R&D collaboration agreement aiming to evaluate Biomillenia’s microfluidics-based culture platform for phenotypic screening of Amyris’s engineered production strains. Biomillenia will contribute its …
Paris/France – October 7, 2019 – BASF and Biomillenia today announced the signing of a microbiome discovery agreement. The collaboration aims to identify novel dermocosmetic active ingredients involved in promoting skin health. The French company Biomillenia will contribute its unique microbiome-on-a-chip technology that has the ability to grow specific microbes and maintain a higher diversity of living microbes than with …
Biomillenia’s innovative skincare product development pipeline was rewarded with the maximum amount of non-dilutive funding from the Innov’up Leader PIA program by BPIFrance Financement. We are proud to have been selected as a winner of this product development grant that will support the creation of novel skincare solutions that act through modulation of the microbiota of the human skin and …
Ability to identify novel bacterial strains based on functional traits at speeds and volumes never previously seen Partners will be able to create and build tailored, proprietary culture collection with previously unknown microbes Applications across industries – consumer health, food, animal health and agriculture Paris, France, 1st February, 2019 – Biomillenia, a company focused on restoring a robust and resilient …
Collaboration data presented at 3rd Annual European Microbiome Congress Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes Paris, France, and London, UK, November 28, 2017—Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.V. (NASDAQ: QGEN, Frankfurt …
Paris, France, December 1st, 2016—BIOMILLENIA was selected as winner of the “Pitch Your Microbes” competition by the jury members at the European Microbiome Congress. The prize gives BIOMILLENIA access to the Johnson & Johnson Innovation JLINX facility. “This special recognition is a great support from the experts in the field valuing BIOMILLENIA’s unique capabilities for the discovery and development of non-GMO microbial …
Paris, France, October 4, 2016—BIOMILLENIA announces its collaboration with the life science business of Merck on the development of an improved enzyme used in vaccine production processes. Following a successful technology evaluation project employing BIOMILLENIA’s proprietary droplet-based microfluidic cell culture and screening technology platform, BIOMILLENIA and Merck will collaborate on the development of a market-leading enzyme in Merck’s portfolio of …
Paris, France, August 15, 2016—BIOMILLENIA, an innovator in microbe strain development for the manufacturing of strains, natural ingredients and enzymes is delighted to announce the formation of its new scientific advisory board. The world-class team, consisting of leading experts from Europe and the U.S. who have made significant contributions in biotechnology, biological engineering, enzyme technology and microfluidics, will be chaired …
Paris, France, March 14, 2016—French President Mr. Hollande visited today BIOMILLENIA at its new laboratories and office during the inauguration of the Pierre-Gilles de Gennes Institute in Paris. Scientific founder Andrew Griffiths (right on picture) explained to Mr. Hollande the BIOMILLENIA ultrahigh-throughput microfluidics platform for developing tailor-made enzymes and production strains. This novel disruptive technology platform allows the culturing and …
Paris, France, February 23rd, 2016 BIOMILLENIA will move its laboratories and office to the newly built business incubator at the Pierre-Gilles de Gennes Institute in Paris, France. Since starting operations in 2015, BIOMILLENIA entered into several agreements with leading companies in the US and Europe for developing improved versions of enzymes and production strains. The relocation of BIOMILLENIA to the IPGG …
